Singapore's Hilleman Laboratories announced Thursday it will advance the rVSV-based Bundibugyo Ebola vaccine candidate — designated by WHO as the most promising against the strain — toward human trials. [1]

The announcement lands against an epidemic with no countermeasure in hand: the outbreak's ledger, which this paper tracked passing 3,262 confirmed as response access shrank, now stands at 3,442 cases and 1,521 dead. [2]

Precision matters here. A candidate moving toward trials is not a trial start, not a result, not an approved vaccine, and not a dose anywhere near the Democratic Republic of Congo. The rVSV design is a label, not a vial; the years between a designation and deployment are the honest content of the story, and Thursday's record contains no timeline for crossing them.

What the announcement does establish is the epidemic's first countermeasure-instrument record: a named developer, a named design, a WHO label. The questions it leaves — trial timeline, outbreak-scale manufacture and its funding, any protocol under which doses could reach this outbreak — remain unanswered. The response community's demand for a dose schedule is aimed at a trial that does not yet exist to schedule from — the gap between candidate and vial, measured in years, is the divergence this brief refuses to close.

-- NORA WHITFIELD, Chicago